---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034897"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:23:52.591187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart Q3 net loss narrows to $14.1M; COVID Phase 2b sentinel enrollment near completion

## Summary
- Q3 revenue $4.9M (up from $2.1M YoY) from BARDA contracts; net loss per share $0.06 vs $0.11.
- Cash $58.7M; expects runway into 2026; R&D $15.1M, G&A $4.3M.
- Sentinel cohort enrollment of Phase 2b COVID vaccine trial expected to complete Nov 2024; 10,000-participant phase could start early 2025 if safety data favorable.
- FDA requested new clinical data for norovirus program; Vaxart created more potent GI.1 and GII.4 constructs.
- Preclinical data on HPV mucosal vaccine published in Vaccines in August 2024.

## SEC filing metadata
- accession: 0001437749-24-034897
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774924034897/0001437749-24-034897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774924034897/vxrt20240820_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034897
- JSON: https://secwatch.observer/filing/0001437749-24-034897.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.